|
000
| 01357nam 2200325zi 4500 |
|---|
| 001 | 9.919266 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20230313123350 |
|---|
| 006 | m o d f |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 230118t20232023onc o f000 0 eng d |
|---|
| 020 | |a9780660471624 |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aH164-346/2023E-PDF |
|---|
| 245 | 00|aGuidance document : |bconduct and analysis of comparative bioavailability studies. |
|---|
| 264 | 1|aOttawa, ON : |bHealth Canada = Santé Canada, |c2023. |
|---|
| 264 | 4|c©2023 |
|---|
| 300 | |a1 online resource (35 pages) |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aIssued also in French under title: Ligne directrice : conduite et analyse des études de biodisponibilité comparatives. |
|---|
| 500 | |a"Date Adopted: 2012/02/08. Revised Date: 2023/01/30. Effective Date: 2018/09/01 (for submissions filed on or September 1, 2018)." |
|---|
| 650 | 0|aDrugs|xTesting|xGovernment policy|zCanada. |
|---|
| 650 | 0|aDrugs|xBioavailability|zCanada. |
|---|
| 710 | 1 |aCanada. |bHealth Canada, |eissuing body. |
|---|
| 775 | 08|tLigne directrice : |w(CaOODSP)9.919268 |
|---|
| 795 | |tGuidance document |w9.852787 |
|---|
| 856 | 40|qPDF|s636 KB|uhttps://publications.gc.ca/collections/collection_2023/sc-hc/H164-346-2023-eng.pdf |
|---|